Evidence map›Paper›PMID 27856425›Full record

ArticleCancer immunology research2016

PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.

Marcela A Haro, Chad A Littrell, Zhaojun Yin, Xuefei Huang, Karen M Haas

Abstract read
In one paragraph

Article in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. IgM promotes antitumor immunity to a Tn-expressing solid tumor.Journal for immunotherapy of cancer · 2026
    Article
  2. Review
  3. Review
  4. Noncanonical B Cells: Characteristics of Uncharacteristic B Cells.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. B Cell Subsets Differentially Contribute to the T Cell-Independent Memory Pool.Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  10. Article
  11. Type I IFN, Ly6CMolecular cancer therapeutics · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1-Infected Corneas.Journal of immunology (Baltimore, Md. : 1950) · 2018
    Article
  16. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marcela A HaroDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Chad A LittrellDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Zhaojun YinDepartment of Chemistry, Michigan State University, East Lansing, Michigan.
Xuefei HuangDepartment of Chemistry, Michigan State University, East Lansing, Michigan.
Karen M HaasDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina. kmhaas@wakehealth.edu.
Wake Forest University · USMichigan State University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Virus-Like Particle Based Antigen Display as Multi-component Anticancer VaccinesR01CA149451 · NCI · MICHIGAN STATE UNIVERSITY · PI HUANG, XUEFEI · 2011 to 2015
$2.4M
Regulation of Memory B Cell Responses to Polysaccharide AntigensR01AI118876 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HAAS, KAREN M · 2015 to 2019
$1.9M
PD-1 regulation of protective immune responses to Tn+ tumorsF31CA183567 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HARO, MARCELA ADRIANA · 2014 to 2016
$114k
NCI NIH HHS F31 CA183567NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA149451NIAID NIH HHS R01 AI118876
6 · The paper itself

Abstract

Tn is a carbohydrate antigen uniquely exposed on tumor mucins and, thus, an ideal target for immunotherapy. However, it has been difficult to elicit protective antibody responses against Tn antigen and other tumor-associated carbohydrate antigens. Our study demonstrates this can be attributed to PD-1 immuno-inhibition. Our data show a major role for PD-1 in suppressing mucin- and Tn-specific B-cell activation, expansion, and antibody production important for protection against Tn-bearing tumor cells. These Tn/mucin-specific B cells belong to the innate-like B-1b cell subset typically responsible for T cell-independent antibody responses. Interestingly, PD-1-mediated regulation is B cell-intrinsic and CD4

Indexed as

AnimalsAntigens, Tumor-Associated, CarbohydrateCell Line, TumorFemaleHumansImmunizationImmunoglobulin GImmunoglobulin MMice, Inbred C57BLMice, TransgenicMucinsNeoplasmsProgrammed Cell Death 1 ReceptorAntigens, Tumor-Associated, CarbohydrateImmunoglobulin GImmunoglobulin MMucinsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorTn antigen

Identifiers

PMID27856425
PMCPMC5373664
OpenAlexW2553751227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.